Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Objectives:
Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk
myelodysplastic syndromes (MDS).
Secondary: To evaluate response duration, survival and side effects of the treatment.